Periodical
Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenström Macroglobulinemia
| العنوان: | Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenström Macroglobulinemia |
|---|---|
| المؤلفون: | Sarosiek, Shayna R, von Keudell, Gottfried R., Paludo, Jonas, Salkar, Monika, Agatep, Barnabie, Franco, Anjali, Crawford, Samuel, Pacia, Michelle, Castillo, Jorge J. |
| المصدر: | Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p3780-3780, 1p |
| مستخلص: | Background:In patients with Waldenström macroglobulinemia (WM), continuous once-daily ibrutinib-based therapy has been associated with long-term progression-free survival. In addition, patients who continued ibrutinib-based treatment had better survival outcomes than those who discontinued treatment within the first few years. Evidence based on a single-center retrospective study suggests that dose reduction (DR) can be used to effectively manage ibrutinib-related adverse events (AEs) and avoid early treatment discontinuation. However, real-world data on outcomes in patients with WM after ibrutinib DR are limited. In this real-world study, we analyzed short-term (1-year follow-up) dosing patterns and time to treatment discontinuation (TTD) in patients with WM, with and without DR, who were receiving first-line (1L) ibrutinib. |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edo Supplemental Index ejs64705146 868 6 Periodical serialPeriodical 867.996154785156 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=ejs64705146&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edo&genre=article&issn=00064971&ISBN=&volume=142&issue=1%2C%20Number%201%20Supplement%201&date=20231102&spage=3780&pages=3780-3780&title=Blood&atitle=Real-World%20Outcomes%20Following%20Dose%20Modifications%20of%20First-Line%20Ibrutinib%20in%20Patients%20with%20Waldenstr%C3%B6m%20Macroglobulinemia&id=DOI:10.1182/blood-2023-181925 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenström Macroglobulinemia
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Sarosiek%2C+Shayna+R%22">Sarosiek, Shayna R</searchLink><br /><searchLink fieldCode="AR" term="%22von+Keudell%2C+Gottfried+R%2E%22">von Keudell, Gottfried R.</searchLink><br /><searchLink fieldCode="AR" term="%22Paludo%2C+Jonas%22">Paludo, Jonas</searchLink><br /><searchLink fieldCode="AR" term="%22Salkar%2C+Monika%22">Salkar, Monika</searchLink><br /><searchLink fieldCode="AR" term="%22Agatep%2C+Barnabie%22">Agatep, Barnabie</searchLink><br /><searchLink fieldCode="AR" term="%22Franco%2C+Anjali%22">Franco, Anjali</searchLink><br /><searchLink fieldCode="AR" term="%22Crawford%2C+Samuel%22">Crawford, Samuel</searchLink><br /><searchLink fieldCode="AR" term="%22Pacia%2C+Michelle%22">Pacia, Michelle</searchLink><br /><searchLink fieldCode="AR" term="%22Castillo%2C+Jorge+J%2E%22">Castillo, Jorge J.</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p3780-3780, 1p ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Background:In patients with Waldenström macroglobulinemia (WM), continuous once-daily ibrutinib-based therapy has been associated with long-term progression-free survival. In addition, patients who continued ibrutinib-based treatment had better survival outcomes than those who discontinued treatment within the first few years. Evidence based on a single-center retrospective study suggests that dose reduction (DR) can be used to effectively manage ibrutinib-related adverse events (AEs) and avoid early treatment discontinuation. However, real-world data on outcomes in patients with WM after ibrutinib DR are limited. In this real-world study, we analyzed short-term (1-year follow-up) dosing patterns and time to treatment discontinuation (TTD) in patients with WM, with and without DR, who were receiving first-line (1L) ibrutinib. ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1182/blood-2023-181925
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 1
[StartPage] => 3780
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenström Macroglobulinemia
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sarosiek, Shayna R
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => von Keudell, Gottfried R.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Paludo, Jonas
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Salkar, Monika
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Agatep, Barnabie
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Franco, Anjali
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Crawford, Samuel
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pacia, Michelle
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Castillo, Jorge J.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 02
[M] => 11
[Text] => November 2023
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 00064971
)
[1] => Array
(
[Type] => issn-print
[Value] => 15280020
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 142
)
[1] => Array
(
[Type] => issue
[Value] => 1, Number 1 Supplement 1
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Blood
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |